Category Archives: Patient Communication

Email Marketing's Growing Maturity

Email marketing is still very much with us, despite much talk of its demise. But, writes Peter Houston, it has moved on from its “spammy” adolescence. Scary tales of The-Next-Big-Social-Thing killing off the first digital marketing blockbuster have been building for years. McKinsey’s November 2013  iConsumer survey reported a 20 percent decline in email usage […]
Also posted in Marketing, Op-Ed, social media, Strategy | Tagged , , | Leave a comment

CHC Stresses Privacy, First Amendment, Self-Regulation at DC meeting

This week members of the Coalition for Healthcare Communication (CHC) met to discuss issues in healthcare communications and marketing like privacy and security, off-label advertising and the Sunshine Act along with an update on the overall DC environment. Nuala O’Connor, president and CEO of the Center for Democracy and Technology started the group off with […]
Also posted in Advertising, Marketing, Sales | Leave a comment

Are You Aging Well? Ask Pfizer

I’ve just finished taking Pfizer’s #FOGO (Have A Fear of Getting Old?) test on getold.com. I passed with flying colors. The results assured me that I would have a hell of a time aging during these advancing years and that the last lap of my life would be a breeze. Why? I wonder. Was it […]
Also posted in healthcare, Op-Ed, patient education, social media | Tagged , , | Leave a comment

Abrams Talks Social Media at DIA

“It doesn’t turn me on to send a warning letter.” –Tom Abrams, during a Q&A at DIA.  Instead of repeating his yearly Drug Information Association (DIA) conference claim that social media guidance remains among the FDA’s Office of Prescription Drug Promotion’s (OPDP) “highest priorities,” to be published in due course, Tom Abrams, director of OPDP, […]
Also posted in Advertising, E-Media, FDA, Legal, Marketing, Meetings, Regulatory, social media, Strategy, Technology | Tagged , , , , , | Leave a comment

Social Media Questions Pharma Companies Should Be Asking

For pharma companies, entering the social media scene is not as simple as just creating a Facebook page or learning how to tweet in 140 characters or less. Social media poses a regulatory and litigation maze that must be carefully navigated. Here, Mathew dos Santos and Lori Leskin provide some insight into the most pressing questions companies are, […]
Also posted in E-Media, FDA, Guest Blog, multimedia, Regulatory, social media | Tagged , , | Leave a comment
  • Categories

  • Meta